Drug Profile

SPIRO 2102

Alternative Names: SPIRO-2102

Latest Information Update: 28 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Spirovant Sciences
Developer Sumitomo Pharma America
Class Gene therapies
Mechanism of Action Cystic fibrosis transmembrane conductance regulator expression modulators; Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Dec 2023 No recent reports of development identified for preclinical development in Cystic-fibrosis in USA (Inhalation, Aerosol)
30 Dec 2019 Sumitomo Dainippon Pharma acquired all rights of five companies namely Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Altavant Sciences and Spirovant Sciences from Riovant and transferred it to Sumitovant Biopharma (a subsidiary of Sumitomo Dainippon Pharma)
01 Nov 2019 Preclinical trials in Cystic fibrosis in USA (Inhalation)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com